Mylan announced on Monday that it has entered into a settlement and license agreement with Pfizer relating to Mylan's abbreviated new drug application filed with the U.S. Food and Drug Administration for celecoxib capsules in 50-mg, 100-mg, 200-mg and 400-mg strengths.
Teva Pharmaceutical Industries announced on Friday that the U.S. District Court for the Northern District of West Virginia has denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100-, 200- and 400-mg capsules.
Pfizer announced plans to submit a new drug application with the Food and Drug Administration for palbociclib, which is used for the first-line systemic treatment of post-menopausal women with advanced or metastatic breast cancer.
With Pfizer's targeted takeover of AstraZeneca, there's been much talk about inversion, or the practice of re-domiciling a company's headquarters to another country in an effort to save on corporate taxes.
Mylan last week announced that it filed suit against the Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on celecoxib capsules, the generic equivalent of Pfizer's Celebrex.
U.S. pharmaceutical firm Pfizer this morning confirmed discussions with AstraZeneca regarding a possible merger. If the transaction goes through, it's expected that the two companies will combine under a new U.K-incorporated holding company.
Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.
Pfizer Consumer Healthcare on Monday teamed up with actor and active volunteer Josh Duhamel for the Advil Relief in Action campaign, which features the #ReliefinAction Pledge on Facebook and a Mobile Relief Center tour making approximately 100 stops throughout the country.
Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.